Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-10-28
2010-10-19
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S356500
Reexamination Certificate
active
07816391
ABSTRACT:
A compound of formula (I):and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.
REFERENCES:
patent: 4250178 (1981-02-01), Bucher et al.
patent: 2004/0142930 (2004-07-01), Yamada et al.
patent: 2006/0223852 (2006-10-01), Gillespie et al.
patent: 2006/0235028 (2006-10-01), Li et al.
patent: 2007/0225280 (2007-09-01), Anderson et al.
patent: 2008/0269288 (2008-10-01), McCoull et al.
patent: 2009/0221660 (2009-09-01), Tomkinson et al.
patent: 2009/0221663 (2009-09-01), Packer et al.
patent: 2009/0264401 (2009-10-01), Gill et al.
patent: 2009/0306075 (2009-12-01), McCoull et al.
patent: 2009/0312372 (2009-12-01), McCoull et al.
patent: 2010/0022589 (2010-01-01), McCoull et al.
patent: 0188094 (1986-07-01), None
patent: 1219609 (2002-07-01), None
patent: 1600442 (2005-11-01), None
patent: 1889842 (2008-02-01), None
patent: 1894919 (2008-03-01), None
patent: WO 02/20463 (2002-03-01), None
patent: WO 02/34711 (2002-05-01), None
patent: WO 03/015774 (2003-02-01), None
patent: WO 2004/065351 (2004-08-01), None
patent: WO 2004/089470 (2004-10-01), None
patent: WO 2004/089896 (2004-10-01), None
patent: WO 2005/016877 (2005-02-01), None
patent: WO 2005/023761 (2005-03-01), None
patent: WO 2005/054200 (2005-06-01), None
patent: WO 2005/060963 (2005-07-01), None
patent: WO 2005/108359 (2005-11-01), None
patent: WO 2005/121110 (2005-12-01), None
patent: WO 2006/000371 (2006-01-01), None
patent: WO 2006/048750 (2006-05-01), None
patent: WO 2006/050476 (2006-05-01), None
patent: WO 2006/074244 (2006-07-01), None
patent: WO 2006/106054 (2006-10-01), None
patent: WO 2006/106423 (2006-10-01), None
patent: WO 2006/113261 (2006-10-01), None
patent: WO 2006/125958 (2006-11-01), None
patent: WO 2006/132197 (2006-12-01), None
patent: WO 2006/132436 (2006-12-01), None
patent: WO 2006/134467 (2006-12-01), None
patent: WO 2007/007041 (2007-01-01), None
patent: WO 2007/017649 (2007-02-01), None
patent: WO 2007/052843 (2007-05-01), None
patent: WO 2007/053657 (2007-05-01), None
patent: WO 2007/058346 (2007-05-01), None
patent: WO 2007/089683 (2007-08-01), None
patent: WO 2007/107470 (2007-09-01), None
patent: WO 2007/115935 (2007-10-01), None
patent: WO 2007/125049 (2007-11-01), None
patent: WO 2008/012532 (2008-01-01), None
patent: WO 2008/053194 (2008-05-01), None
patent: WO 2008/099145 (2008-08-01), None
patent: WO 2008/142986 (2008-11-01), None
patent: WO 2009/010416 (2009-01-01), None
patent: WO 2009/098501 (2009-08-01), None
Katsuno K, et al., “Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level,” Journal of Pharmacology and Experimental Therapeutics, Jan. 2007, 320(1), 323-330.
Boyle “Recent advances in the discovery of 11b-HSD1 inhibitors” Current Opinion in Drug Discovery and Development 11:495-511 (2008).
Jean et al. “Inhibitors of 11{hacek over (a)}-HSD1: A Potential Treatment for the Metabolic Syndrome” Current Topics in Medicinal Chemistry 8(17): 1508-1523 (2008).
Shorvon, “Pyrrolidone derivatives” Lancet 358(9296):1885-1892 (2001).
Blake et al. “Discovery of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-HSD1” Gordon Research Conference on Medicinal Chemistry, Colby-Sawyer College, New London, NH, USA (Aug. 2007).
deSchoolmeester et al. “An increase in obesity is associated with increased 11βHSD1 activity but not expression in mature human subcutaneous adipocytes” Association for the Study of Obesity (ASO) and Adipose Tissue Discussion Group, Institute of Child Health, London (Nov. 9, 2006).
Mayers “11β-hydroxysteroid dehydrogenase type 1: a tale of (fat) mice to men” Abstract and Presentation, Obesity and its Treatment, Society for Medicines Research (Sep. 25, 2008).
Barf et al. Recent progress in 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) inhibitor development Drugs of the Future 31(3):231-243 (2006).
Dostert et al. “Studies on the neuroleptic benzamides I. Synthesis and antidopaminergic properties of new pyrimidine derivatives” European Journal of Medicinal Chemistry 17(5):437-444 (1982).
Hirokawa et al. “Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity” J Med. Chem. 46(5):702-715 (2003).
Hussein et al. “β-Oxoanilides in heterocyclic synthesis: An expeditious synthesis of new polyfunctionally substituted pyridine and pyrazole derivatives” Journal of Heterocyclic Chemistry 45(6):1819-1823 (2008).
Langlois et al. “Studies on the neuroleptic benzamides II. Synthesis and pharmacological evaluation of new 6-azabrendane derivatives” European Journal of Medicinal Chemistry 17(5):445-447 (1982).
Packer Martin John
Scott James Stewart
Stocker Andrew
Whittamore Paul Robert Owen
AstraZeneca AB
Hui San-ming
Morgan & Lewis & Bockius, LLP
Zarek Paul
LandOfFree
Chemical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4167606